| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Dihydrojasmonic acid targets pathways involved in plant growth, defense, and stress signaling as a naturally occurring jasmonate derivative. In biomedical research, it exhibits potential anti-inflammatory and anticancer properties. As a jasmonate derivative, it may interact with jasmonate receptors and signaling pathways. The compound's anti-inflammatory activity may involve modulation of inflammatory cytokine production. Its anticancer properties suggest interactions with pathways regulating cell proliferation and apoptosis. Further research is needed to identify its specific molecular targets in mammalian systems.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Dihydrojasmonic acid exhibits potential bioactivity in biomedical research, including anti-inflammatory and anticancer properties. As a jasmonate derivative, its effects on cell signaling and gene expression have been characterized. The compound's purity of ≥98% supports its use in research applications. These in vitro findings support its applications in plant biology, proteomics research, and biomedical research. Further studies are needed to fully characterize its biological activities and mechanisms of action.
|
| ln Vivo |
In vivo studies of Dihydrojasmonic acid are limited as the compound is primarily used as a research chemical. As a naturally occurring jasmonate derivative, it plays a role in plant growth, defense, and stress signaling in vivo. Its anti-inflammatory and anticancer properties suggest potential for in vivo evaluation in biomedical research models. However, comprehensive in vivo pharmacological studies specifically targeting Dihydrojasmonic acid are not well documented in the available literature. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme assays for Dihydrojasmonic acid typically involve testing its activity in plant signaling pathways. For jasmonate signaling studies, the compound's ability to activate jasmonate-responsive gene expression is assessed using reporter gene assays. For anti-inflammatory activity, enzyme assays measuring COX, LOX, or other inflammatory enzymes may be performed. The compound's purity and identity are assessed using analytical chemistry methods such as gas chromatography, nuclear magnetic resonance spectroscopy, and mass spectrometry. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for Dihydrojasmonic acid involve culturing cells to evaluate its anti-inflammatory and anticancer activities. For anti-inflammatory studies, immune cells are treated with the compound and stimulated with inflammatory stimuli; cytokine production is measured by ELISA. For anticancer studies, cancer cell lines are treated with the compound and cell viability is assessed using MTT or similar colorimetric assays. Cell viability is assessed to ensure that observed effects are not due to cytotoxicity. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Dihydrojasmonic acid would be conducted to evaluate its anti-inflammatory and anticancer activities. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. For anticancer studies, tumor-bearing animals would be treated and tumor growth monitored. Parameters assessed would include body weight, organ weights, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Dihydrojasmonic acid reflect its nature as a small jasmonate derivative. It has a molecular weight of 212.29 and the molecular formula C12H20O3. The compound appears as a colorless to light yellow to light orange clear liquid. It is stored frozen at <0°C and is light and heat sensitive. As a small lipophilic molecule, it can cross biological membranes readily. The compound is expected to be metabolized through standard xenobiotic pathways. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Dihydrojasmonic acid has been evaluated in the context of its use as a research chemical. As a naturally occurring jasmonate derivative, it is expected to have a favorable safety profile at research concentrations. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile for pharmaceutical applications.
|
| References | |
| Additional Infomation |
9,10-Dihydrojasmonic acid is a jasmonic acid ester derivative whose function is related to that of jasmonic acid. It has been reported that dihydrojasmonic acid exists in peas, and relevant data are available for reference.
Dihydrojasmonic acid (CAS# 3572-64-3) is a naturally occurring jasmonate derivative with the molecular formula C12H20O3 and a molecular weight of 212.29. It appears as a colorless to light yellow to light orange clear liquid and has a purity of ≥98%. The compound is involved in plant growth, defense, and stress signaling. It exhibits potential bioactivity in biomedical research, including anti-inflammatory and anticancer properties. The compound is stored frozen at <0°C and is light and heat sensitive. It is a useful biochemical for proteomics research. It is intended for research use only. |
| Molecular Formula |
C12H20O3
|
|---|---|
| Molecular Weight |
212.29
|
| Exact Mass |
212.141
|
| CAS # |
3572-64-3
|
| PubChem CID |
107126
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.038g/cm3
|
| Boiling Point |
361.9ºC at 760 mmHg
|
| Flash Point |
186.8ºC
|
| Index of Refraction |
1.472
|
| LogP |
2.636
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
15
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])([H])C([H])([H])C([H])(C([H])([H])C(=O)O[H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
PQEYTAGBXNEUQL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H20O3/c1-2-3-4-5-10-9(8-12(14)15)6-7-11(10)13/h9-10H,2-8H2,1H3,(H,14,15)
|
| Chemical Name |
2-(3-oxo-2-pentylcyclopentyl)acetic acid
|
| Synonyms |
Dihydrojasmonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (471.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7105 mL | 23.5527 mL | 47.1054 mL | |
| 5 mM | 0.9421 mL | 4.7105 mL | 9.4211 mL | |
| 10 mM | 0.4711 mL | 2.3553 mL | 4.7105 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
